Rabies Immunoglobulins: Combating a Neglected Tropical Disease -"How IgY(ΔFc) Technology Delivers Equity, Safety, and Scalability"
The Global Challenge of Rabies Prophylaxis
Rabies, a neglected tropical disease (NTD), poses a critical threat in low-resource regions. Traditional equine rabies immunoglobulins (ERIG) remain vital for post-exposure prophylaxis (PEP) in high-risk cases (Category III exposure). However, ERIG production has dwindled due to ethical, economic, and scalability challenges. Human rabies immunoglobulin (HRIG), while an alternative, is costly and scarce, leaving developing countries underserved.
IgY(ΔFc) Immunoglobulins: Innovation for Equity
Good Biotech Corp. pioneers a transformative approach to rabies prevention with IgY(ΔFc) immunoglobulins, produced via hyper-immunized ducks. This innovation addresses global gaps in rabies prophylaxis by combining scalability, safety, and affordability. Recognized by the World Health Organization (WHO) as a vital tool for neglected tropical diseases, our IgY(ΔFc) technology offers:
- Superior Safety: Non-allergenic compared to equine IgG.
- Scalability: Rapid, high-yield production to meet global demand.
- Affordability: Cost-effective manufacturing for low-resource settings.
- Ethical Compliance: Eliminates reliance on equine serum, aligning with modern animal welfare standards.
Why Partner with Good Biotech Corp.
Our IgY(ΔFc) platform redefines rabies prophylaxis by delivering a safer, scalable, and sustainable alternative to ERIG and HRIG. By partnering with us, you contribute to equitable access to life-saving biologics while advancing global health priorities.
Partner with Us
Good Biotech Corp. welcomes collaborations to expand access to life-saving rabies prophylaxis. Together, we can advance global health equity through innovative biologics.
Contact Us to Explore Opportunities
Reach out to discuss how we can partner to address this urgent public health need:
📧 partnership@good-biotech.com